CJC-1295 (No DAC)
CJC-1295 is a Growth Hormone Releasing Hormone (GHRH) analogue. It stimulates the release of growth hormone, leading to improved sleep, muscle growth, and fat loss.
Common Dosage
100mcg - 300mcg per dose
Category
Anti-Aging
- Increased muscle mass
- Fat loss
- Improved sleep quality
- Anti-aging effects
CJC-1295 was developed by ConjuChem Biotechnologies as a long-acting GHRH (Growth Hormone Releasing Hormone) analogue. The original CJC-1295 with DAC (Drug Affinity Complex) had an extended half-life of 6–8 days due to covalent albumin binding. The version without DAC (also called Mod GRF 1-29) has a much shorter half-life (~30 minutes) that more closely mimics the natural pulsatile GH release pattern. The research peptide community predominantly uses the No DAC version to preserve physiological pulsatility, which is considered important for maintaining pituitary sensitivity.
CJC-1295 (No DAC) binds to GHRH receptors on pituitary somatotroph cells, stimulating the synthesis and release of growth hormone. Unlike direct GH administration, it works through the body's own pituitary, preserving feedback mechanisms. When combined with a GHRP like Ipamorelin, the two peptides act synergistically — CJC-1295 amplifies the GH pulse while Ipamorelin triggers it via a separate ghrelin receptor pathway.
- Growth hormone optimization in age-related GH decline
- Body composition improvement — increased lean mass and reduced body fat
- Sleep quality enhancement through GH's role in deep sleep architecture
- Recovery acceleration from training and injury
- Skin quality improvement via IGF-1 upregulation
- Bone mineral density support
Anti-Aging Protocol Outcomes
Integrative medicine practitioners using CJC-1295 + Ipamorelin as a growth hormone optimization protocol in adults 40–65 have reported improvements in body composition, sleep quality, and subjective energy levels over 3–6 month courses. IGF-1 levels in monitored cases typically rise 30–50% from baseline.
Sleep Architecture Improvement
Users consistently report deeper, more restorative sleep within the first 1–2 weeks of bedtime CJC-1295 + Ipamorelin dosing. The mechanism aligns with growth hormone's known role in slow-wave sleep promotion — a relationship well-documented in sleep medicine literature.
Body Recomposition in Athletes
Competitive bodybuilders and fitness athletes using CJC-1295 report improvements in fat loss during caloric restriction while maintaining lean muscle — consistent with GH's known lipolytic and anabolic properties. The effect is subtle compared to direct GH injection but considered more physiologically appropriate.
- Potential for increased IGF-1 levels — elevated IGF-1 has been theoretically associated with cancer promotion; individuals with a history of cancer should consult an oncologist
- Water retention and temporary edema are common, particularly in the initial weeks
- Numbness or tingling in extremities (carpal tunnel-like symptoms) with higher doses
- Pituitary desensitization is a concern with continuous use — cycling protocols are strongly recommended
- Hypoglycemia risk if injected too close to meals
- Not approved for use in any country — regulatory status is research compound
- Water retention
- Numbness in extremities (rare)